Englander Institute for Precision Medicine

Epigenetic control of immunoevasion in cancer stem cells.

TitleEpigenetic control of immunoevasion in cancer stem cells.
Publication TypeJournal Article
Year of Publication2024
AuthorsGalassi C, Esteller M, Vitale I, Galluzzi L
JournalTrends Cancer
Date Published2024 Sep 06
ISSN2405-8025
Abstract

Cancer stem cells (CSCs) are a poorly differentiated population of malignant cells that (at least in some neoplasms) is responsible for tumor progression, resistance to therapy, and disease relapse. According to a widely accepted model, all stages of cancer progression involve the ability of neoplastic cells to evade recognition or elimination by the host immune system. In line with this notion, CSCs are not only able to cope with environmental and therapy-elicited stress better than their more differentiated counterparts but also appear to better evade tumor-targeting immune responses. We summarize epigenetic modifications of DNA and histones through which CSCs evade immune recognition or elimination, and propose that such alterations constitute promising therapeutic targets to increase the sensitivity of some malignancies to immunotherapy.

DOI10.1016/j.trecan.2024.08.004
Alternate JournalTrends Cancer
PubMed ID39244477

Weill Cornell Medicine Englander Institute for Precision Medicine 413 E 69th Street
Belfer Research Building
New York, NY 10021